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Background: In 2006, the Mauritanian Ministry of Health adopted a new therapeutic strategy based on the systematic
use of artemisinin-based combination therapy (ACT), artesunate-amodiaquine and artemether-lumefantrine, for the
first- and second-line treatment of uncomplicated malaria, respectively, regardless of Plasmodium spp. In the Saharan
zone of the country, recent studies have shown that Plasmodium vivax largely predominates over Plasmodium
falciparum. Anti-malarial drug response of P. vivax has not been evaluated in Mauritania. The aim of the present study
was to evaluate the clinical efficacy and tolerance of chloroquine to treat P. vivax malaria in Mauritanian patients.
Methods: Plasmodium vivax-infected patients aged > 6 months old were enrolled in Nouakchott and Atar in
September–October 2013. Chloroquine was administered at the standard dose of 25 mg base/kg body weight over
three days. Patients were followed until day 28, according to the standard 2009 World Health Organization protocol.
Results: A total of 128 patients (67 in Nouakchott and 61 in Atar) were enrolled in the study. Seven patients (5.5%)
were either excluded or lost to follow-up. Based on the per protocol analysis, chloroquine efficacy (adequate clinical
and parasitological response) was 100%. Treatment was well-tolerated. One patient was excluded on day 1 due to
urticaria and treated with artesunate-amodiaquine.
Conclusions: Although the current national treatment guideline recommends artesunate-amodiaquine for the first-line
treatment of uncomplicated malaria, including P. vivax malaria, chloroquine may still have an important role to play in
anti-malarial chemotherapy in Mauritania. Further epidemiological studies are required to map the distribution of
P. vivax and P. falciparum in the country.
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Malaria is one of the major public health problems in
Mauritania. Every year, between 200,000 and 300,000
malaria cases are officially notified, mostly without la-
boratory confirmation of clinical diagnosis [1]. Most
Plasmodium falciparum infections occur in the sahelian
south of Mauritania. In contrast, recent epidemiological* Correspondence: salem0606@yahoo.fr
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article, unless otherwise stated.data indicate that Plasmodium vivax infections predom-
inate in the Saharan zone of the country [2,3].
The epidemiology of P. vivax malaria is not well
known in the neighbouring countries, such as Mali and
Senegal. Malaria risk due to P. vivax is limited in Algeria
[4]. Plasmodium vivax was eliminated from Morocco in
2010 [5]. Although P. vivax had been registered in the
past in Cape Verde islands, only P. falciparum has been
diagnosed during the last 20 years [6]. Elsewhere in
Africa, P. vivax occurs in São Tomé and Príncipe, in
some East African countries, and in Madagascar [7-9].BioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Study sites in Mauritania.
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West Africa [10]. As a consequence, most West African
countries have adopted artemisinin-based combination
therapy (ACT) for the treatment of acute uncomplicated
falciparum malaria. Since 2006, in line with the regional
anti-malarial drug policies, the Mauritanian Ministry of
Health recommends the use of artesunate-amodiaquine
and artemether-lumefantrine for the first- and second-
line treatment of acute uncomplicated malaria, respect-
ively, without making a distinction between different
malaria species. Although ACT has been used to treat
mixed P. falciparum and P. vivax infections in endemic
areas, where mixed infections with these two Plasmo-
dium species occur frequently, the efficacy of different
forms of ACT to specifically treat P. vivax infections is
not well established.
In other parts of the world, where P. vivax is endemic,
chloroquine is still the drug of choice to treat this infec-
tion [11]. Chloroquine is generally effective against
P. vivax, well-tolerated, safe in young children and preg-
nant women, and much cheaper than ACT. The efficacy
of chloroquine to treat P. vivax malaria has not been
evaluated in Mauritania. The present single-arm study
was performed to evaluate the efficacy and tolerance of
chloroquine in P. vivax-infected, symptomatic patients
in the Saharan zone in Mauritania where P. vivax has
emerged in recent years.Methods
Study sites
The clinical studies were conducted simultaneously in
two study sites in central and northern Mauritania:
Nouakchott (18°05′02″ north, 15°58′42″ west), the cap-
ital city of Mauritania, and Atar (20°31′06″ north, 13°
03′13″ west, the regional capital of the Adrar) (Figure 1).
In 2013, it was estimated that the population in
Nouakchott was 899,887 inhabitants [Office National de la
Statistique, Nouakchott, Mauritania]. Based on previous
studies, that showed a high prevalence of laboratory-
confirmed P. vivax malaria in the northern districts of
Nouakchott [2,3], Teyarett health centre was selected for
the present study. In 2012, the health centre recorded
more than 1,000 P. vivax malaria, confirmed by rapid
diagnostic test for malaria.
Atar lies within the Sahara desert and is situated 440 km
to the northwest of Nouakchott. The estimated population
of Atar in 2013 was 58,803 inhabitants [Office National de
la Statistique, Nouakchott, Mauritania]. The study was
conducted in the regional hospital with a functional basic
laboratory. Although there are no previous malaria epi-
demiological data in Atar, a preliminary pilot study in
2012 showed laboratory-confirmed cases of P. vivax in this
city [Ould Ahmedou Salem MS, unpublished data].Patients
Patients spontaneously consulting at the health centres in
September–October 2013 were enrolled after informed
written consent if the following criteria were met: age >
6 months old, P. vivax monoinfection with parasitaemia >
250 asexual parasites/μL, presence of fever (axillary
temperature ≥ 37.5°C) or history of fever 48 h preceding
medical consultation, and ability to swallow oral medication
[12]. Patients with signs of severe and complicated P. vivax
malaria (coma, impaired consciousness, respiratory distress,
convulsions) [13,14], mixed Plasmodium species, severe
malnutrition, fever due to concomitant diseases, and history
of allergic reaction to chloroquine were excluded.
Laboratory examinations, treatment, and follow-up
Fingerprick capillary blood was collected to prepare
Giemsa-stained thin and thick smears to be examined
under the microscope, according to standard World Health
Organization (WHO) procedures [15]. Blood samples
were also imbibed onto Whatman 3MM filter paper (GE
Healthcare Life Sciences, Amersham Place, Little Chalfont
Bucks, UK) and dried to store parasite DNA.
Chloroquine (batch no. CAMH0027 containing 240 mg
chloroquine phosphate, an equivalent of 150 mg chloro-
quine base; Micro Labs Limited, Bangalore, India) was ad-
ministered once daily on day 0 (10 mg base/kg body
weight), day 1 (10 mg base/kg body weight), and day 2
(5 mg base/kg body weight) at the standard total dose of
25 mg base per kg body weight. Each dose administration
was supervised by one of the team members, and patients
were observed for at least 30 minutes after drug intake for
possible vomiting or adverse effects. In case of vomiting






Mean age (±SD, range), yr 23.9 ± 16.5 (3–62) 30.9 ± 17.9 (2–80)
Age groups
Under 5 years old, n (%) 5 (7.5) 2 (3.3)
5 – 18 years old, n (%) 25 (37.3) 17 (27.9)
>18 years old, n (%) 37 (55.2) 42 (68.9)
Sex ratio (M/F) 0.91 (32/35) 0.85 (28/33)
Mean weight
(±SD, range), kg




38.8 ± 1.2 (36.0–41.2) 39.0 ± 1.5 (36.0–41.6)
Proportion of patients







988 (834–1 170) 2 280 (1 850–2 810)
290–14 300 460–30 100
The mean age and parasitaemia were significantly higher (P < 0.05) in Atar than in
Nouakchott. There was no significant difference (P > 0.05) in the mean weight
and body temperature of the two patient populations in Nouakchott and Atar.
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and the patient was observed for an additional 30 minutes.
In case of repeated vomiting, the patient was withdrawn
from the study protocol and rescue treatment was admin-
istered (parenteral quinine, 8 mg base/kg body weight,
three times a day for seven days, or quinine followed
by artesunate-amodiaquine or artemether-lumefantrine as
soon as the patient tolerated oral medication). Paraceta-
mol (10 mg/kg body weight) was administered to all pa-
tients three times a day for fever and headache.
Patients were followed on days 1, 2, 3, 7, 14, 21, and
28 [12]. Fingerprick capillary blood was collected for
blood examination from day 2 to day 28 and imbibed
onto Whatman 3MM filter paper from day 7 to 28, in-
cluding any unscheduled visit due to an occurrence of
fever, clinical aggravation, or treatment failure. Patients
who failed to respond to chloroquine treatment were
treated with artesunate-amodiaquine, as recommended
by the national guideline for anti-malarial treatment.
Study end points
The primary end point was determined on day 28 and
classified into one of the following categories: early treat-
ment failure (ETF), late clinical failure (LCF), late parasito-
logical failure (LPF), or adequate clinical and parasitological
response (ACPR), as defined by the WHO [12]. Treatment
failure refers to one of the following outcomes: ETF, LCF,
or LPF. ACPR is synonymous with treatment success.
PCR and genotyping
Parasite DNA was extracted from filter papers using the
Chelex method [16]. Plasmodium species identity was
determined using 18S rRNA as the target molecule [17].
Genotypes of paired pre-treatment and recurrent parasites
on or after day 7 were compared using microsatellite ana-
lysis [18]. At present, there is no standard protocol to dis-
tinguish among P. vivax recrudescence (i.e. reappearance
of the same parasite population as that of pre-treatment
infection), reinfection (i.e. appearance of different parasite
populations), and relapse (reappearance of the same para-
site populations or appearance of different parasite popu-
lations from reactivation of hypnozoites) with certainty.
Statistical analysis
The sample size of 50 patients (plus 20% to anticipate
losses due to exclusions, withdrawals, and lost-to-follow-
up), i.e. a minimum of 60 patients, was calculated on the
basis of an expected failure rate of 5%, 10% precision,
and a confidence level of 95% [12].
As recommended in the WHO protocol [12], per proto-
col analysis of the percentage of ACPR and Kaplan-Meier
survival analysis were performed to calculate the probability
of the time to treatment failure during the 28-day follow-
up period. Data were entered into the standard pre-programmed Excel worksheet provided by the Global
Malaria Programme, WHO, for per protocol analysis. Sur-
vival curves were plotted and analyzed using Prism 4.0
(GraphPad Software, Inc., La Jolla, CA) software. Quanti-
tative variables were compared between the patient popu-
lation in Nouakchott and Atar using the unpaired t-test.
The significance level was P < 0.05.
Ethical approval
The study was reviewed and approved by an ad hoc
Mauritanian national ethics committee and the ethics
committee of the WHO (Geneva, Switzerland). The pur-
pose of the study was explained to the patients (and
their parents or legal guardians for children and adoles-
cents) in local dialect. Informed written consent was ob-
tained from adult patients or caretakers of paediatric
patients aged less than 12 years old. For adolescents
aged between 12 and 18 years old, an informed written
consent was obtained from both the patients themselves
and their parents or legal guardians.
Results and discussion
A total of 128 patients were enrolled in the study: 67 in
Nouakchott and 61 in Atar. Of 128 enrolled patients, 3
(2.3%, all in Nouakchott) were excluded after inclusion
for protocol violation on day 1 (n = 1), withdrawal of
consent on day 1 (n = 1), and development of urticaria
on day 1 (n = 1) (Table 1). Additional six patients were
Table 2 Per-protocol analysis of chloroquine efficacy to
treat P. vivax malaria in the Saharan zone in Mauritania
Outcome Nouakchott Atar
Number of enrolled patients 67 61
Exclusion after enrollment, n (%) 3 (4.5) 0
Lost-to-follow-up, n (%) 2 (3.0) 4 (6.6)
Per protocol population, n 62 57
PCR-uncorrected outcome*
Early treatment failure, n (%) 0 0
Late clinical failure (LCF), n (%) 0 0
Late parasitological failure, n (%) 0 0
Adequate clinical and parasitological
response, n (%)
62 (100) 57 (100)
*PCR correction was not performed due to 100% efficacy (per protocol
population) on day 28.
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and four (on days 3, 7, 14, and 21) in Atar. Both patients
who were lost to follow-up in Nouakchott (a 24-year-old
male presenting with a body temperature of 41.2°C and
1,180 asexual parasites/μL on day 0, and a 35-year-old
male with a body temperature of 37.8°C and 471 asexual
parasites/μL on day 0) were afebrile from day 1 to day
21 and aparasitaemic from day 7. Among 4 patients lost
to follow-up in Atar, one 40-year-old male presented
with fever at the time of consultation (40.1°C with 1,600
asexual parasites/μL), and 3 (5, 24, and 28-year old pa-
tients) had a history of fever less than 48 h preceding med-
ical consultation and parasitaemia ranging from 600 to
3,300 asexual parasites/μL. All of these four patients were
afebrile from day 1 and aparasitaemic from day 2 until the
last day when they were seen. The per protocol population
consisted of 119 patients followed until day 28, 62 in
Nouakchott and 57 patients in Atar. PCR showed that all
included patients were infected by P. vivax.
In both Nouakchott and Atar, per protocol analysis
showed 100% chloroquine efficacy (Table 2). Due to the
absence of treatment failure, PCR correction using micro-
satellites and survival curve analysis were not performed.
This is the first evaluation of chloroquine efficacy
against P. vivax in West Africa. The results indicate that
chloroquine is highly efficacious and well-tolerated in the
predominantly Moor population residing in Nouakchott
and Atar. Fever and parasitaemia were rapidly cleared.
Generalized urticaria developed 2–3 hours after the first
dose of chloroquine in a 7-year old boy. The patient was
immediately treated with injectable dexamethasone and
oral antihistaminics, and the patient was excluded from
the protocol by precaution and treated with artemether-
lumefantrine.
Although chloroquine was found to be highly effective
in the present study, chloroquine-resistant P. vivax has
been reported from some foci in Asia, Oceania, SouthAmerica, and more recently, from Madagascar and
Ethiopia in eastern Africa [11,19-23]. In the most recent
study conducted in Ethiopia, recurrent parasitaemia was
observed in 10 (9.3%) of 108 enrolled patients (per
protocol population) on day 28 [23]. Three of 10 cases
of recurrent parasitaemia had identical genotype as the
day-0 parasites. Furthermore, in that study recurrence was
observed in 32% of patients treated with chloroquine by
day 42. However, despite reappearance of parasite popula-
tions with identical genotype as the pre-treatment para-
sites, the origin of recurrent P. vivax parasitaemia after
treatment cannot be attributed at present to recrudes-
cence, reinfection, or relapse with certitude due to tech-
nical limitations. A co-administration of chloroquine and
primaquine may reduce the recurrence rate due to
relapse.
A nationwide survey to establish an up-to-date epidemi-
ology of glucose-6-phosphate dehydrogenase deficiency,
which presents a potential risk of primaquine-induced
haemolysis, and clinical studies on chloroquine co-
administered with primaquine are warranted to further
assess and determine the role of chloroquine for the
treatment of P. vivax malaria in Mauritania.
Conclusions
More precise, up-to-date epidemiological data on the
distribution of P. vivax and glucose-6-phosphate de-
hydrogenase deficiency in Mauritania are required be-
fore implementing concrete actions to control and
eliminate malaria from the country. Based on the results
of the present clinical data, the current national treat-
ment guideline that recommends the systematic use of
artesunate-amodiaquine for the first-line treatment of
acute uncomplicated P. falciparum and P. vivax malaria
in Mauritania may need to be revised if further studies
confirm chloroquine efficacy in other sites in the
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